logo

For the Inventor, By the Inventor

Orsay, France

Emile R Bisagni

This inventor holds 19 USPTO granted patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Centre National De La Recherche Scientifique, Agence Nationale De Valorisation De La Recherche (Anvar), Adir Et Compagnie. Active years: 1981-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Emile R Bisagni. Retrieved from https://idiyas.com/inventor/emile-r-bisagni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 78.9


Average Co-Inventor Count = 4.5

ph-index = 6

Forward Citations = 93(Granted Patents)


Company Filing History:

goldMedal7 out of 5,383 
 
Centre National De La Recherche Scientifique
 patents
silverMedal3 out of 338 
 
Agence Nationale De Valorisation De La Recherche (Anvar)
 patents
bronzeMedal2 out of 368 
 
Adir Et Compagnie
 patents
4. 2 out of 1,853 
 
National Institute of Health and Medical Research
 patents
5. 1 out of 46 
 
Agence Nationale De Valorisation De La Recherche
 patents
6. 1 out of 162 
 
Institut Curie
 patents
7. 1 out of 11 
 
Institute Curie
 patents
8. 1 out of 1 
 
Institute of Experimental Botany, Academy of Science of the Czech Republic
 patent
9. 1 out of 192 
 
Rhone-Poulenc Sante
 patents
10. 1 out of 1,546 
 
Sanofi
 patents
11. 1 out of 297 
 
Universitè De Montpellier
 patents
12. 3 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1981-2012

Loading Chart...
Loading Chart...
Areas of Expertise:
Purine Derivatives
Anti-Proliferative Properties
HIV Inhibiting Compounds
Indole-Derived Compounds
Pyridinone Derivatives
Ellipticine Compounds
Pyridoindole Derivatives
Antitumor Properties
Skin Diseases
Medicinal Uses
Biological Applications
Pharmaceutical Compositions
19 patents (USPTO):Explore Patents
1. 8163762 - Purine derivatives having, in particular, anti-proliferative properties, and their biological uses (2012-04-24),
2. 7989467 - Use of indole-derived compounds for the preparation of a medicament that can be used to treat diseases related to the splicing process (2011-08-02),
3. 7115608 - Pyridinone and pyridinethione derivatives having HIV inhibiting properties (2006-10-03),
4. 6683079 - 3-(amino-or aminoalkyl) pyridinone derivatives and their use for the treatment of HIV related diseases (2004-01-27),
5. 6451822 - 3-(Amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases (2002-09-17),
6. 6316456 - Purine derivatives having, in particular, antiproliferative properties, and their biological uses (2001-11-13),
7. 6162811 - Ellipticine compounds (2000-12-19),
8. 6015820 - 4-Aryl-thio-pyridin-2(1H)-ones, medicines containing them and their uses (2000-01-18),
9. 5919791 - Ellipticine compounds (1999-07-06),
10. 5091388 - Pyridobenzoindole derivatives, their preparation and compositions which (1992-02-25),
11. 4966971 - Method for preparing 1-chloro-5-alkylisoquinolines condensed with (1990-10-30),
12. 4870180 - 1,2-dihydro-4-methyl-1-oxo-5H-pyrido(4,3-b)indoles and the process for (1989-09-26),
13. 4835160 - Derivatives of pyridoindole, having anti-tumor properties (1989-05-30),
14. 4465691 - (3,4';4,5)-Pyrido (3,2-g)-furo coumarins or (3,4-h) pyrido psoralens (1984-08-14),
15. 4464354 - (3,4-c)-Pyrido psoralens, process of preparation, application in (1984-08-07),

Title: Emile R. Bisagni: Innovator in Pharmaceutical and Biochemical Patents

Introduction: Emile R. Bisagni, an influential inventor based in Orsay, France, has made notable contributions to the fields of biochemistry and pharmaceutical sciences. With a total of 19 patents to his name, Bisagni's research focuses on innovative compounds that have significant applications in treating various diseases.

Latest Patents: Among his latest inventions are purine derivatives, which exhibit anti-proliferative properties and have potential applications as pharmaceutical and herbicidal compositions. One specific patent describes the compound 2(1-R hydroxymethylpropylamino)-6-benzylamino-9-isopropyl purine, which is designed for treatment in pharmaceutical settings.

Additionally, Bisagni has developed indole-derived compounds intended for creating medicaments that address diseases associated with the splicing process of pre-messenger RNAs. His research targets severe conditions such as Frasier syndrome, frontotemporal dementia linked to chromosome 17, Leigh syndrome, atypical cystic fibrosis, Alzheimer's disease, and various cancers, including breast and colon cancer.

Career Highlights: Throughout his career, Emile R. Bisagni has been involved with esteemed research institutions, including the National Centre for Scientific Research (Centre National de la Recherche Scientifique). His work has propelled advancements in the pharmaceutical industry, focusing on innovative solutions to pressing medical challenges.

Collaborations: Bisagni has collaborated with distinguished colleagues like Christian Rivalle and Chi Hung Nguyen, enhancing the scope of his research through shared expertise and innovative ideas. These collaborations have played a pivotal role in developing his groundbreaking inventions.

Conclusion: Emile R. Bisagni's impressive portfolio of patents highlights his commitment to advancing medicinal chemistry and addressing complex health issues. His innovations in purine derivatives and indole-derived compounds represent a significant step forward in the quest for effective treatments, proving the essential role of inventors in bridging research and practical application in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…